U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610798) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations' on May 14.
Brief Summary: This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Advance Solid Tumors
Colon and Rectal Cancer
Non - Small Cell Lung Cancer NSCLC
Pancreatic Adenocarcinoma Advanced or Metastatic
Ovarian Cancer
Endometrial...